Pharmacological characterization of endogenous acetylcholine release from primary septal cultures.
A detailed investigation of endogenous acetylcholine (ACh) release from primary embryonic septal cultures is described in this study. Applications of veratridine (25 microM) or increasing extracellular concentrations of K(+) (6-100 mM) induced robust increases of endogenous ACh release ( approximately 500-15,000 fmol/well/10 min). Release stimulated with K(+) (25 mM) was sustainable and did not differ significantly over 180 min. ACh release was dependent on extracellular choline and decreased proportionally to choline concentrations (0-10 microM). For example, after 30 min of stimulation with K(+) (25 mM), release in the absence of extracellular choline was approximately 25% of that associated with 10 microM choline. The vesicular transport blocker vesamicol (0-5 microM) almost completely prevented stimulated and basal ACh release at the highest concentration evaluated, which suggests a mostly vesicular mode of release in this model. The M(2)-like muscarinic receptor antagonist AF-DX 384 (0-10 microM) enhanced stimulated ACh release ( approximately 150% at the highest concentration evaluated), whereas the nonspecific muscarinic receptor agonist oxotremorine (0-10 microM) decreased stimulated release (approximately 60% at the highest concentration evaluated), suggesting that functional muscarinic autoreceptors exist in primary embryonic septal cultures. Novel findings concerning ACh release from primary embryonic septal cultures are reported herein, and the demonstration of ACh release gives further credit to the use of these cultures for studying cholinergic system functioning and in relation to physiology and pathology.
Auld
D S
DS
Douglas Hospital Research Centre, Faculty of Medicine, McGill University, Montreal, Quebec, Canada.
Day
J C
JC
Mennicken
F
F
Quirion
R
R
D000109:Acetylcholine / Q000378:metabolism*; D000818:Animals; D002478:Cells, Cultured; D002794:Choline / Q000502:physiology*; D002795:Choline O-Acetyltransferase / Q000378:metabolism*; D002851:Chromatography, High Pressure Liquid; D004305:Dose-Response Relationship, Drug; D004347:Drug Interactions; D004622:Embryo, Mammalian / Q000378:metabolism*; D018721:Muscarinic Agonists / Q000494:pharmacology; D009467:Neuromuscular Depolarizing Agents / Q000494:pharmacology; D010095:Oxotremorine / Q000494:pharmacology; D010276:Parasympatholytics / Q000494:pharmacology; D010880:Piperidines / Q000494:pharmacology; D010890:Pirenzepine / Q000031:analogs & derivatives / Q000494:pharmacology; D011188:Potassium / Q000494:pharmacology; D051381:Rats; D020665:Septum of Brain / Q000378:metabolism*; D013997:Time Factors; D014701:Veratridine / Q000494:pharmacology
D018721:Muscarinic Agonists; D009467:Neuromuscular Depolarizing Agents; D010276:Parasympatholytics; D010880:Piperidines; C065959:AFDX 384; C006189:vesamicol; D010890:Pirenzepine; D010095:Oxotremorine; D014701:Veratridine; D002795:Choline O-Acetyltransferase; D002794:Choline; D000109:Acetylcholine; D011188:Potassium